Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma

79Citations
Citations of this article
61Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background:Multiple myeloma (MM) is an incurable clonal plasma cell malignancy. The constitutive expression of HIF-1α in MM suggests that inhibition of HIF-1α-mediated transcription represents an interesting target in MM.Methods:As p300 is a crucial co-activator of hypoxia-inducible transcription, disrupting the complex HIF-1α/p300 to target HIF activity appears to be an attractive strategy.Results:We reported that chetomin, an inhibitor of HIF-1α/p300 interaction, exhibits antitumour activity in human myeloma cell lines and primary MM cells from patients.Conclusions:Our data suggest that chetomin may be of clinical value in MM and especially for patients characterised by a high EP300/HIF-1α expression and a poor prognosis.

Cite

CITATION STYLE

APA

Viziteu, E., Grandmougin, C., Goldschmidt, H., Seckinger, A., Hose, D., Klein, B., & Moreaux, J. (2016). Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma. British Journal of Cancer, 114(5), 519–523. https://doi.org/10.1038/bjc.2016.20

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free